Riferimento farmaci
Blinatumomab
Blinatumomab is a medicine in the class oncology. It is used for acute lymphocytic leukemia.
- Classe del farmaco: Oncology
- Indicato per: acute lymphocytic leukemia
Ultimo aggiornamento Fonti: US FDA label
Per operatori sanitari — solo a scopo di riferimento. Questa pagina è una sintesi breve, non è un parere medico e non sostituisce il RCP ufficiale né il giudizio clinico. Verificare sempre prima di prescrivere o dispensare.
Il contenuto clinico di questa pagina è disponibile solo in inglese.
In breve
- Classe del farmaco
- Oncology
- Codice ATC
- L01FX07
- Dosaggi comuni
- 35 mcg
- Interazioni note
- 14 (Moderata: 13 · Minore: 1)
- Nomi commerciali
- 2
- Paesi e mercati
- 2
Per cosa si usa
Come agisce
Bispecific CD19-directed CD3 T-cell engager that connects CD3 on T-cells with CD19 on benign and malignant B-cells, activating T-cells and causing redirected lysis of CD19+ cells.
Dose abituale nell'adulto (sintesi del foglio illustrativo)
MRD-positive B-cell precursor ALL: patients 45 kg or more 28 mcg/day by continuous IV infusion on Days 1-28 of each 42-day cycle (14-day treatment-free interval); 1 induction cycle then up to 3 consolidation cycles
Gravidanza e allattamento
- Gravidanza
- Unsafe May cause fetal harm based on mechanism; no human data. Can cause B-cell lymphocytopenia in exposed infants. Verify pregnancy status before treatment.
- Allattamento
- Unsafe Advise not to breastfeed during treatment and for 48 hours after the last dose.
Effetti indesiderati segnalati
- Pyrexia
- Infusion-related reactions
- Headache
- Infection
- Musculoskeletal pain
- Neutropenia
Avvertenze in evidenza
- Cytokine release syndrome, which may be life-threatening or fatal, occurred. Interrupt or discontinue and treat with corticosteroids as recommended.
Controindicazioni
- Known hypersensitivity to blinatumomab or any component of the formulation.
Chi deve prestare attenzione
- CRS: monitor; interrupt for severe CRS and discontinue permanently for life-threatening CRS.
- Neurological toxicities including ICANS; consider seizure prophylaxis in Down syndrome patients.
- Serious infections occurred in approximately 25% of patients; consider prophylactic antibiotics and monitor.
Informare il farmacista o il medico di gravidanza o allattamento, malattie renali o epatiche, allergie e di ogni altro farmaco o integratore assunto.
Interazioni principali (14)
- Blinatumomab + Carbamazepine Moderate
- Blinatumomab + Cyclosporin Moderate
- Blinatumomab + Ethosuximide Moderate
- Blinatumomab + Phenytoin Moderate
- Blinatumomab + Quinidine Moderate
- Blinatumomab + Quinine Moderate
- Blinatumomab + Siponimod Moderate
- Blinatumomab + Sirolimus Moderate
- Blinatumomab + Tacrolimus Moderate
- Blinatumomab + Theophylline Moderate
Per gli utenti Pro+
Sblocca la pagina completa
Crei un account e avvii una prova di Pro+ per aprire la monografia completa di Blinatumomab: dosi, gravidanza e allattamento, effetti indesiderati, avvertenze e tutte le interazioni.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Paediatric dosing
- How to give it
- Pharmacokinetics
- Patient counselling points
Provi Pro+ gratis per 14 giorni sul web. Nessuna carta.
Altri farmaci della stessa classe
Domande frequenti
What is Blinatumomab used for?
Blinatumomab is a medicine in the class oncology. It is used for Acute lymphocytic leukemia.
What side effects have been reported with Blinatumomab?
Pyrexia, Infusion-related reactions, Headache, Infection, Musculoskeletal pain, Neutropenia. Serious warning: Cytokine release syndrome, which may be life-threatening or fatal, occurred.
Can Blinatumomab be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. May cause fetal harm based on mechanism; no human data. Can cause B-cell lymphocytopenia in exposed infants. Verify pregnancy status before treatment. Breastfeeding: Unsafe. Advise not to breastfeed during treatment and for 48 hours after the last dose.
What does Blinatumomab interact with?
MediHelp lists 14 known interactions for Blinatumomab. Moderate: 13 · Minor: 1. The most serious include Carbamazepine, Cyclosporin, Ethosuximide.
Monografie complete, posologie e verifica delle interazioni nell'app MediHelp
Apra il riferimento completo, verifichi le interazioni tra più farmaci e usi gli strumenti di posologia nell'app MediHelp.
